| 1 |
35580565 | Gilteritinib in isolated breast relapse of FLT3positive acute myeloid leukemia: a case report and review of literature. | 2022 May 17 |
2 |
| 2 |
33531064 | Multiplexed single-cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells. | 2021 Feb 2 |
3 |
| 3 |
34362484 | [Efficacy of Different Doses of Daunorubicin Induced Chemotherapy in Patients with Newly Diagnosed Primary Acute Myeloid Leukemia Under 65 Years Old]. | 2021 Aug |
1 |
| 4 |
31672129 | The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report. | 2019 Oct 31 |
1 |
| 5 |
32009807 | Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain. | 2019 |
2 |
| 6 |
29705536 | High dose daunorubicin: New standard of care for FLT3 ITD mutant AML. | 2018 Jun |
1 |
| 7 |
28632487 | Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia. | 2017 Aug 20 |
2 |
| 8 |
27268085 | Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia. | 2016 Jul 21 |
1 |
| 9 |
27374090 | Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress. | 2016 Jul 26 |
1 |
| 10 |
22829255 | Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies. | 2012 Mar |
1 |
| 11 |
19625780 | The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. | 2009 Aug 15 |
1 |
| 12 |
16982329 | Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation. | 2006 Oct |
1 |
| 13 |
15626738 | FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). | 2005 May 1 |
1 |
| 14 |
15304385 | Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. | 2004 Dec 15 |
1 |